Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Wednesday, November 30, 2005 at 12:00 AM

E-mail E-mail article      Print Print      Share Share

Firm tests therapy on leukemia

Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia...

By Seattle Times business staff

Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia (CLL).

SGN-40, a genetically engineered monoclonal antibody, is already being studied for multiple myeloma and non-Hodgkin's lymphoma in other early trials.

The Bothell company also said SGN-40 received "orphan drug" designation for CLL from the Food and Drug Administration. The designation, for treatment of relatively rare diseases, means Seattle Genetics will have seven years of market exclusivity if the drug is approved.

The company's stock lost 8 cents, or 1.6 percent, to close at $4.93 Tuesday. It fell 3 more cents in after-hours trading.

E-mail E-mail article      Print Print      Share Share

More Business & Technology

UPDATE - 09:46 AM
Exxon Mobil wins ruling in Alaska oil spill case

UPDATE - 09:32 AM
Bank stocks push indexes higher; oil prices dip

UPDATE - 08:04 AM
Ford CEO Mulally gets $56.5M in stock award

UPDATE - 07:54 AM
Underwater mortgages rise as home prices fall

NEW - 09:43 AM
Warner Bros. to offer movie rentals on Facebook

More Business & Technology headlines...

advertising


Get home delivery today!

Video

Advertising

AP Video

Entertainment | Top Video | World | Offbeat Video | Sci-Tech

Marketplace

 
Most read
Most commented
Most e-mailed
 
 

Most viewed imagesMore

Advertising